Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-11-27
2007-11-27
Powers, Fiona T (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S406000, C548S361100, C548S364100
Reexamination Certificate
active
11104556
ABSTRACT:
The present invention relates to pyrazole derivatives of the formula I, their preparation and their use in pharmaceuticals:in which X, R1, R1a, R2, R3, R4and n are as defined in the claims, which are useful pharmaceutically active compounds for the therapy and prophylaxis of illnesses, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I are capable of modulating the body's production of cyclic guanosine monophosphate “cGMP” and are generally suitable for the therapy and prophylaxis of illnesses which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the formula I, to their use for the therapy and prophylaxis of the abovementioned illnesses and for preparing pharmaceuticals for this purpose, and also to pharmaceutical preparations which comprise the compounds of the formula I.
REFERENCES:
patent: 4072498 (1978-02-01), Moon et al.
patent: 4325962 (1982-04-01), Rainer
patent: 5434178 (1995-07-01), Talley et al.
patent: 5574168 (1996-11-01), Kuo et al.
patent: 5977108 (1999-11-01), Kikuchi et al.
patent: 6166027 (2000-12-01), Straub et al.
patent: 6180656 (2001-01-01), Furstner et al.
patent: 6451805 (2002-09-01), Straub et al.
patent: 2141124 (1972-02-01), None
patent: 2141125 (1972-02-01), None
patent: 0 667 345 (1995-08-01), None
patent: 2104932 (1972-04-01), None
patent: WO-97/02244 (1977-01-01), None
patent: WO 98/16223 (1998-04-01), None
patent: WO 98/16507 (1998-04-01), None
patent: WO 98/23619 (1998-06-01), None
Brioni et al., International Journal of Impotence Research, 14, 8-14, 2002.
Erceg et al., Brain Research, 1036, 115-121, 2005.
Hadoke, Pharmacology & Therapeutics, 89, 233-254, 2001.
Hobbs, Trends in Pharmacological Sciences, 18(12), 484-491, Dec. 1977.
Hobbs et al., Vascular Pharmacology, 40, 149-154, 2003.
Kojda et al., Pharmaceutica Acta Helvetiae, 73, 27-35, 1998.
Monfort et al., Neuroscience, 104(4), 1119-1125, 2001.
Teng et al., European Journal of Pharmacology, 320, 161-166, 1977.
Vesely et al., Diabetes, 26(4), 308-313, Apr. 1977.
Flanders et al., “Prevention of Type 1 Diabetes from Laboratory to Public Health,”Autoimmunity29(3), 235-246 (1999).
Gnichtel et al.,Chemical Abstracts111:57617 (1989).
Guo et al., “Preparation of Condensed 1-benzyl-3-arylpyrazole Derivatives as Blood Platelet Aggregation Inhibitors,”Chemical Abstracts, 3:125:33633m, 903 (1996).
Huang et al.,Chemical Abstracts, 98:107203 (1983).
Ignarro, “Regulation of Cytosolic Guanylyl Cyclase by Porphyrins and Metalloporphyrins,”Advances in Pharmacology26:35-65 (1994).
Ko, et al., “YC-1, A Novel Activator of Platelet Guanylate Cyclase,”Blood84(12):4226-4233 (1994).
Peat, “The Epidemiology of Asthma,”Current Opinion in Pulmonary Medicine, 2:7-15 (1996).
Pettibone, et al., “A Structurally Novel Stimulator of Guanylate Cyclase With Long-Lasting Hypotensive Activity In The Dog,”European Journal of Pharmacology, 116:307-312 (1985).
Rosenbloom et al., “Non-Insulin Dependent Diabetes Mellitus (NIDDM) in Minority Youth: Research Priorities and Needs,”Clinical Pediatrics, 37(2):143-152 (1988).
Shimanskaya et al.,Chemical Abstracts, 69:112873 (1968).
Vesely, “B complex Vitamins Activate Rat Guanylate Cyclase and Increase Cyclic GMP Levels,”European Journal of Clinical Investigation15:258-262 (1985).
Vesely, “Phencyclidine Stimulates Guanylate Cyclase Activity,”Biochemical and Biophysical Research Communications, 88(4):1244-1248 (1979).
Wu, et al., “YC-1 Inhibited Human Platelet Aggregation through NO-Independent Activation of Soluble Guanylate Cyclase,”British Journal of Pharmacology116:1973-1978 (1995).
Yoshina et al., “Pyrazole Derivatives,”Chemical Abstracts, 25(84):180207p, 575 (1976).
Yoshina et al.,Chemical Abstracts, 88:105211, 1978.
Yu, et al., “Inhibition of Platelet Function by A02131-1, A Novel Inhibitor of cGMP-Specific Phosphodiesterase, In Vitro and In Vivo,”Blood87(9):3758-3767 (1996).
Yu, et al., “Mechanism of Anti-Proliferation Caused by YC-1, an Indazole Derivative, in Cultured Rat A10 Vascular Smooth-Muscle Cells,”Biochem. J.306:787-792 (1995).
Yu, et al., “Vasorelaxant Effect of Isoliquiritigenin, A Novel Soluble Guanylate Cyclase Activator, In Rat Aorta,”British Journal of Pharmacology114:1587-1594 (1995).
Schindler Ursula
Schönafinger Karl
Strobel Hartmut
Aventis Pharma Deutschland GmbH
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Powers Fiona T
LandOfFree
Pyrazole derivatives, their preparation and their use in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazole derivatives, their preparation and their use in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazole derivatives, their preparation and their use in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3887456